IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.829
-0.038 (-4.38%)
At close: Jan 14, 2025, 4:00 PM
0.810
-0.019 (-2.29%)
After-hours: Jan 14, 2025, 5:59 PM EST
IO Biotech Employees
IO Biotech had 68 employees as of December 31, 2023. The number of employees increased by 11 or 19.30% compared to the previous year.
Employees
68
Change (1Y)
11
Growth (1Y)
19.30%
Revenue / Employee
n/a
Profits / Employee
-$1,328,529
Market Cap
54.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 68 | 11 | 19.30% |
| Dec 31, 2022 | 57 | 25 | 78.13% |
| Dec 31, 2021 | 32 | 21 | 190.91% |
| Dec 31, 2020 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
IOBT News
- 5 days ago - IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer - GlobeNewsWire
- 25 days ago - IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - GlobeNewsWire
- 2 months ago - IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - IO Biotech Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study - GlobeNewsWire
- 3 months ago - IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 4 months ago - IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - GlobeNewsWire
- 4 months ago - IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - GlobeNewsWire